Related Experiment Video
Updated: Mar 22, 2026

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
Approach to the Management of Pediatric-Onset Anti-N-Methyl-d-Aspartate (Anti-NMDA) Receptor Encephalitis: A Case
J Nicholas Brenton1, Joshua Kim2, Richard H Schwartz3
1Department of Neurology, Division of Pediatric Neurology, University of Virginia, Charlottesville, VA, USA jnb8h@virginia.edu.
Insights
Anti-NMDA receptor encephalitis is treatable with immunotherapy, leading to good recovery in pediatric patients. However, chronic immunotherapy poses significant risks, necessitating careful benefit-risk assessment and further research.
Area of Science:
- Neurology
- Immunology
- Pediatrics
Background:
- Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis is a treatable autoimmune neurological disorder.
- The impact of acute and chronic immunotherapy on the natural history of anti-NMDA receptor encephalitis is not fully understood.
Purpose of the Study:
- To evaluate the treatment course and clinical outcomes of pediatric patients with anti-NMDA receptor encephalitis.
- To assess the efficacy and complications of acute and chronic immunotherapy in this patient population.
Main Methods:
- Retrospective chart review of pediatric patients diagnosed with anti-NMDA receptor encephalitis.
- Data collection included demographics, disease manifestations, treatment, and outcomes.
Main Results:
- Ten pediatric patients with anti-NMDA receptor encephalitis were identified.
- All patients received acute immunotherapy and achieved good recovery without neurologic relapse.
- Fifty percent of patients experienced complications from chronic immunotherapy.
Conclusions:
- Acute immunotherapy appears effective for pediatric anti-NMDA receptor encephalitis, leading to good recovery.
- Chronic immunotherapy is associated with significant complications, requiring careful consideration of risks versus benefits.
- Further clinical trials are needed to determine the optimal duration and benefit of long-term immunotherapy.
Abstract:
Anti-N-methyl-d-aspartate (anti-NMDA) receptor encephalitis is a treatable cause of autoimmune encephalitis. It remains unclear if the natural history of this disease is altered by choice of acute therapy or the employment of chronic immunotherapy. Chart review was undertaken for pediatric patients diagnosed with anti-NMDA receptor encephalitis. Data obtained included patient demographics, disease manifestations, treatment course, and clinical outcomes. Ten patients with anti-NMDA receptor encephalitis were identified. All patients were treated with immunotherapy in the acute period, and all patients experienced good recovery. Neurologic relapse did not occur in any patient. All patients received varied forms of chronic immunosuppression to prevent relapses. Complications of chronic immunotherapy occurred in 50% of patients. The benefits of chronic immunotherapy and the duration of use should be carefully weighed against the risks. Complications from immunotherapy are not uncommon and can be serious. Clinical trials assessing the benefit of long-term immunotherapy in this population are needed.
More Related Videos
07:20A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate NMDA Receptor in Blood
Published on: January 9, 2018
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Related Concept Videos
Arboviral Encephalitis
Viral Meningitis
Pharmaceutical Poisoning: Treatment Strategies
Diphtheria
Antiepileptic Drugs: Glutamate Antagonists
Acute Pyelonephritis II: Diagnostic Studies and Management